CLAIMS

1. Use of a pharmaceutical composition containing a therapeutically effective amount of one of

a sulfide, including an organic or inorganic sulfide, a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a combination thereof,

a nitrite, including an organic or inorganic nitrite, a pharmacologically acceptable salt, ester, amide, clathrate, stereoisomer or enantiomer, thereof, and a combination thereof, and

both the sulfide and the nitrite,

in the manufacture of a medicament for the treatment of Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, wherein the relative level of sulfide and nitrite in the medicament is based on whether the mammal is a male or female, specifically, if the mammal is a male, the medicament has a higher level of sulfide to nitrite, and if the mammal is female, the medicament has a lower level of sulfide to nitrite.

2. The use of claim 1 wherein the pharmaceutical composition contains the sulfide.

3. The use of claim 2 wherein the sulfide is a prodrug.

4. The use of claim 3 wherein the prodrug is one of garlic, garlic extract, a cruciferous vegetable, a cruciferous vegetable extract, and a combination thereof.

5. The use of claim 2 wherein the sulfide is diallyl trisulfide (DATS).

6. The use of claim 2 wherein the mammal is a male.

7. The use of claim 1 wherein the pharmaceutical composition contains the nitrite.

8. The use of claim 7 wherein the nitrite is a prodrug.

9. The use of claim 8 wherein the prodrug is one of beetroot, spinach, lettuce, arugula, bok choy, celery, chervil, collard greens, cress, radish, red beetroot, rhubarb, Swiss chard, basil, celeriac, Chinese cabbage, chard, coriander, endive, fennel, kohlrabi, leek, mustard greens, and parsley, the extract thereof, and a combination thereof.

10. The use of claim 8 wherein the prodrug includes a form of nitrate.

11. The use of claim 7 wherein the nitrite is an inorganic nitrite.

12. The use of claim 11 wherein the nitrite is sodium nitrite.

13. The use of claim 7 wherein the mammal is a female.

14. The use of claim 1 wherein the mammal is a human.

15. The use of claim 1 wherein the pharmaceutical composition contains both the sulfide and the nitrite.

16. A pharmaceutical composition comprising;

a therapeutically effective dose of a sulfide, including an organic or inorganic sulfide, a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a combination thereof, and

a therapeutically effective dose of a nitrite, including an organic or inorganic nitrite, a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a combination thereof.

17. The pharmaceutical composition of claim 16 wherein the sulfide is diallyl trisulfide.

18. The pharmaceutical composition of claim 16 wherein the nitrite is sodium nitrite.

19. A pharmaceutical composition containing therapeutically effective amount of one of

a sulfide, including an organic or inorganic sulfide, a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a combination thereof,

a nitrite, including an organic or inorganic nitrite, a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a combination thereof, and

both the sulfide and the nitrite,

for use in the treatment of Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal.